Alternative NSAID for Bartter Syndrome When Indomethacin is Unavailable
Use ibuprofen (15-30 mg/kg/day divided into 3 doses) or celecoxib (2-10 mg/kg/day divided into 2 doses) as the alternative NSAID when indomethacin is unavailable for a child with Bartter syndrome. 1
Medication Selection Algorithm
First-Line Alternative: Ibuprofen
- Dosing: 15-30 mg/kg/day divided into 3 doses 1
- Advantages: Nonselective COX inhibitor like indomethacin, well-established use in Bartter syndrome
- Disadvantages: Requires gastric acid suppression due to COX-1 inhibition
Second-Line Alternative: Celecoxib
- Dosing: 2-10 mg/kg/day divided into 2 doses 1
- Advantages:
- Disadvantages: Less extensive long-term data in pediatric Bartter syndrome
Critical Monitoring Protocol
Gastrointestinal Protection
If using ibuprofen (nonselective COX inhibitor):
- Mandatory co-administration of gastric acid suppression 1
- Preferred: H2 blockers or antacids (NOT proton pump inhibitors initially) 1
- Rationale: PPIs carry risk of hypomagnesemia that compounds renal magnesium wasting in Bartter syndrome 1
- If PPI-associated hypomagnesemia develops: Convert to H2 blockers or switch to celecoxib 1
If using celecoxib:
- Gastric protection may not be mandatory but monitor for symptoms 1
Laboratory Monitoring Schedule
At baseline before NSAID initiation:
- Acid-base status (venous blood gas or total CO2)
- Serum electrolytes (sodium, potassium, chloride, bicarbonate, magnesium)
- Renal function (creatinine, calculate GFR)
- Plasma renin activity and aldosterone
- Urinary calcium excretion
- PTH level 1
After NSAID initiation:
- Week 1-3: Monitor renal function weekly in high-risk patients (those on ACE inhibitors or with baseline renal impairment) 3
- Every 3-6 months for infants and young children: Complete metabolic panel, magnesium, renal function, plasma renin 1
- Plasma renin monitoring: Use to guide NSAID dosing—normalization of renin indicates optimal dose 4
Renal Function Surveillance
- Ensure euvolemia before initiating NSAIDs to minimize nephrotoxicity risk 1
- Monitor for volume-dependent renal failure, interstitial nephritis 3
- Renal ultrasound every 12-24 months to monitor for nephrocalcinosis, kidney stones, obstructive uropathy 1
Gastrointestinal Surveillance
- Upper endoscopy if gastrointestinal symptoms develop (abdominal pain, vomiting, bleeding) 5
- Historical data: With indomethacin, 4/17 patients developed gastric ulcers; with celecoxib, only 3/7 had mild gastritis 2
Clinical Response Indicators
Expected improvements within 4 weeks:
- Reduction in polyuria and polydipsia
- Improved growth velocity (increased Z-scores for height and weight) 2, 4
- Decreased sodium and potassium supplementation requirements 2, 4
- Normalization or reduction of plasma renin activity 4
- Reduced urinary calcium excretion 4
Common Pitfalls to Avoid
Do NOT use potassium-sparing diuretics, ACE inhibitors, or ARBs routinely—these worsen salt wasting and risk life-threatening hypovolemia 1
Do NOT use thiazides—they can cause critical hypovolemia in Bartter syndrome 1
Do NOT supplement with potassium citrate or other non-chloride potassium salts—use only potassium chloride 1
Do NOT withhold salt supplementation (5-10 mmol/kg/day sodium chloride) unless patient has secondary nephrogenic diabetes insipidus with hypernatremic dehydration 1
Do NOT aim for complete normalization of potassium—target serum potassium ≥3.0 mmol/L is reasonable and may not be achievable in all patients 1
Practical Considerations
- Divide supplements throughout the day to maintain steady plasma levels and avoid large fluctuations 1
- For infants on continuous tube feeds, add supplements directly into feeds 1
- Consider celecoxib as first choice if available, given better gastrointestinal safety profile and demonstrated efficacy 2
- Monitor for NSAID "tolerance" over time—some patients show reduced efficacy at school age, which may require dose adjustment or re-evaluation 1